Gemcitabine-nab-paclitaxel Clinical Trials

7 actively recruiting trials across 4 locations

▲ +1 trial since June 2026

Also known as: (G-nP), abraxane

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 1Phase 1/2: 4

Top Sponsors

Zhejiang University1
Verastem, Inc.1
Tianjin Medical University Cancer Institute and Hospital1
Tango Therapeutics, Inc.1
ProDa BioTech, LLC1

Indications

Cancer7
Pancreatic Ductal Adenocarcinoma3
Lung Cancer3
Non Small Cell Lung Cancer2
G12D Mutated KRAS1

Other3 trials

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Phase 2

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Phase 1/2

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Phase 3

Birmingham, Alabama1 trial

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

O'Neal Comprehensive Cancer Center, University of Alabama

Phase 1

Scottsdale, Arizona1 trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Mayo Clinic Scottsdale

Phase 1/2

Los Angeles, California1 trial

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Cedars-Sinai Medical Center

Phase 1/2

Huntersville, North Carolina1 trial

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Carolina BioOncology Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.